SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jdv12176-sup-0001-FigureS1-S9.pptxapplication/PPT279K

Figure S1. AD subjects: relative abundance of hCAP18 mRNA at baseline and day 21 by lesional status and treatment.

Figure S2. NA subjects: relative abundance of hCAP18 mRNA at baseline and day 21 by lesional status and treatment.

Figure S3. Psoriatic subjects: relative abundance of hCAP18 mRNA at baseline and day 21 by lesional status and treatment.

Figure S4. AD subjects: relative abundance of IL-13 mRNA at baseline and day 21 by lesional status and treatment.

Figure S5. Psoriatic subjects: relative abundance of IL-13 mRNA at baseline and day 21 by lesional status and treatment.

Figure S6. NA subjects: relative abundance of IL-13 mRNA at baseline and day 21 by lesional status and treatment.

Figure S7. AD subjects: relative abundance of HDB-3 mRNA at baseline and day 21 by lesional status and treatment.

Figure S8. Psoriatic subjects: relative abundance of HDB-3 mRNA at baseline and day 21 by lesional status and treatment.

Figure S9. NA subjects: relative abundance of HDB-3 mRNA at baseline and day 21 by lesional status and treatment.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.